ATOS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 23:00):

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases...

Stats
Šios dienos apimtis	953 120
Vidutinė apimtis	1.94M
Rinkos kapitalizacija	204.98M
EPS	$0 ( 2024-05-20 )
Kita pelno data	( $-0.0500 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.79
ATR14	$0.00500 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Finn Jonathan	Buy	25 000	Common Stock
2024-03-09	Cigler Tessa	Buy	20 834	Stock Option (right to buy)
2024-03-09	Cigler Tessa	Buy	0
2023-11-15	Weaver Gregory L	Sell	50 000	Common Stock
2023-11-15	Finn Jonathan	Buy	62 500	Stock Option (right to buy)

INSIDER POWER
70.89
Last 98 transactions
Buy: 26 594 652 \| Sell: 4 017 362

Tūris Koreliacija

Ilgas: 0.16 (neutral)

Trumpas: 0.57 (weak)

Signal:(54.157) Neutral

Atossa Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GIFI	0.952
LFMDP	0.948
SG	0.946
RPAY	0.937
RGLS	0.929
SWBI	0.929
CPRT	0.926
PUBM	0.926
MNMD	0.925
DXPE	0.924

10 Labiausiai neigiamai susiję koreliacijos
RETO	-0.916
RGF	-0.911
UONEK	-0.909
EEIQ	-0.909
HRZN	-0.909
TCPC	-0.905
CLEU	-0.901
TTEC	-0.898
QNRX	-0.897
GAN	-0.897

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Atossa Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.07
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.71
( moderate negative )

Atossa Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-23 000.00 (0.00 %)
EPS:	$-0.240

FY	2023
Pajamos:	$0
Bruto pelnas:	$-23 000.00 (0.00 %)
EPS:	$-0.240

FY	2022
Pajamos:	$0
Bruto pelnas:	$-8 000.00 (0.00 %)
EPS:	$-0.210

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.180

Financial Reports:

No articles found.

Atossa Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Atossa Therapeutics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.